The importance of establishing a simple and effective classification scheme to identify such tumours lies in the potential benefit of targeted therapy (PARP inhibitors, platinum drugs) for a much larger group of patients than the relatively few BRCA1 and BRCA2 germline mutation carriers. Here, BRCA2 is linked to neoplasm.